CR20190290A - Improved composition of lansoprazole and simeticone and method for preparing same - Google Patents

Improved composition of lansoprazole and simeticone and method for preparing same

Info

Publication number
CR20190290A
CR20190290A CR20190290A CR20190290A CR20190290A CR 20190290 A CR20190290 A CR 20190290A CR 20190290 A CR20190290 A CR 20190290A CR 20190290 A CR20190290 A CR 20190290A CR 20190290 A CR20190290 A CR 20190290A
Authority
CR
Costa Rica
Prior art keywords
microgranules
simeticone
lansoprazole
concentration
preparing same
Prior art date
Application number
CR20190290A
Other languages
Spanish (es)
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of CR20190290A publication Critical patent/CR20190290A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de administración oral, que comprende la combinación a dosis fija de Simeticona en microgránulos de alta concentración y Lansoprazol o su enantiómero (Dexlansoprazol) en microgránulos de liberación entérica y el proceso para obtener los microgránulos de alta concentración de Simeticona.The present invention relates to an orally administered pharmaceutical composition comprising a fixed-dose combination of simeticone in high-concentration microgranules and lansoprazole or the enantiomer thereof (dexlansoprazole) in enteric-release microgranules. The invention also relates to a method for obtaining the high-concentration simeticone microgranules.The present invention refers to a pharmaceutical composition for oral administration, which comprises the fixed dose combination of Simethicone in high concentration microgranules and Lansoprazole or its enantiomer (Dexlansoprazole) in enteric release microgranules and the process to obtain the high concentration microgranules de Simeticona.The present invention relates to an orally administered pharmaceutical composition comprising a fixed-dose combination of simeticone in high-concentration microgranules and lansoprazole or the enantiomer thereof (dexlansoprazole) in enteric-release microgranules. The invention also relates to a method for obtaining the high-concentration simeticone microgranules.

CR20190290A 2016-12-14 2017-12-13 Improved composition of lansoprazole and simeticone and method for preparing same CR20190290A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2016016587A MX2016016587A (en) 2016-12-14 2016-12-14 Improved composition of lansoprazole and simeticone and method for preparing same.
PCT/IB2017/057904 WO2018109693A1 (en) 2016-12-14 2017-12-13 Improved composition of lansoprazole and simeticone and method for preparing same

Publications (1)

Publication Number Publication Date
CR20190290A true CR20190290A (en) 2019-11-18

Family

ID=62558163

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190290A CR20190290A (en) 2016-12-14 2017-12-13 Improved composition of lansoprazole and simeticone and method for preparing same

Country Status (9)

Country Link
AR (1) AR110183A1 (en)
BR (1) BR112019011966A2 (en)
CL (1) CL2019001462A1 (en)
CO (1) CO2019006693A2 (en)
CR (1) CR20190290A (en)
DO (1) DOP2019000145A (en)
MX (1) MX2016016587A (en)
PE (1) PE20191654A1 (en)
WO (1) WO2018109693A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073384A (en) * 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
WO2008056200A1 (en) * 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone
RU2602745C2 (en) * 2011-12-14 2016-11-20 Дисфар Интернэшнл Б.В. Composition with simeticon

Also Published As

Publication number Publication date
AR110183A1 (en) 2019-03-06
CO2019006693A2 (en) 2019-07-10
DOP2019000145A (en) 2019-08-15
CL2019001462A1 (en) 2019-08-23
WO2018109693A1 (en) 2018-06-21
BR112019011966A2 (en) 2019-11-05
MX2016016587A (en) 2018-06-13
PE20191654A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
CU20190005A7 (en) ORALLY ADMINISTRABLE CHEWING GUM OR AQUEOUS FORMULATIONS INCLUDING A PHARMACEUTICAL AGENT
BR112017008301A2 (en) cannabis extracts and methods of preparation and use
CL2017002817A1 (en) Mono or disubstituted indole derivatives as inhibitors of dengue viral replication
EA201791702A1 (en) THERAPEUTIC TOOLS ON THE BASIS OF GLYCANS AND RELATED METHODS
CO2019000938A2 (en) Nmda spiro-lactam modulators and methods of use thereof
PE20151301A1 (en) PHARMACEUTICAL FORMULATIONS RESISTANT TO IMPROPER HANDLING
BR112017027843A2 (en) pharmaceutical formulations comprising tenofovir and emtricitabine
CL2017001026A1 (en) Methods and compositions particularly for the treatment of attention deficit disorder.
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
CL2016002560A1 (en) Oral solid pharmaceutical dosage form comprising siponimod, a moisture protective agent and optionally a pharmaceutical excipient; Preparation procedure
EA201190161A1 (en) METHOD OF OBTAINING SOLID MEDICINAL FORMS OF SOLIPHENACIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR ORAL ADMINISTRATION
MX2018012618A (en) Oral pharmaceutical compositions of mesalazine.
CR20150266A (en) MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB
CL2015003468A1 (en) Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d.
CR20170604A (en) ORAL SOLID FORMULATION CONTAINING IRINOTECAN AND METHOD OF PREPARATION OF THE SAME
CY1124893T1 (en) MAROPITANTIS MEDICINAL MIXTURE
CL2018003682A1 (en) Oral pharmaceutical composition, comprising a pharmaceutically active agent, at least one bioadhesive cationic polymer and at least two anionic polymers.
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
CL2020000601A1 (en) Pharmaceutical composition.
CR20190290A (en) Improved composition of lansoprazole and simeticone and method for preparing same
ECSP19044926A (en) IMPROVED COMPOSITION OF LANSOPRAZOLE AND SYMETICONE AND PROCESS FOR PREPARING
UY37518A (en) DOSED FORMS OF MODIFIED GASTRORETENTIVE RELEASE FOR OPROZOMIB AND PROCESS FOR MANUFACTURING
PE20160245A1 (en) STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A DISPERSABLE TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS
ECSP16005208A (en) STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS
UY37413A (en) OPROZOMIB IMMEDIATE RELEASE FORMULATIONS